ArticleInflammopharmacology2026
Liposomal curcumin nanocarrier ameliorates synaptic dysfunction after intracerebral hemorrhage.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroinflammation and synaptic dysfunction in the medial prefrontal cortex (mPFC) contribute to cognitive impairment after intracerebral hemorrhage (ICH). Curcumin, a natural polyphenol from Curcuma longa, has anti-inflammatory properties but limited bioavailability.
methodsLiposomal curcumin (Lipo-Cur, 103.2 nm, 74% encapsulation) was prepared by thin-film hydration. Adult male rats were assigned to Sham, ICH (collagenase + empty liposomes), and ICH-Cur (collagenase + Lipo-Cur, 30 mg/kg, i.p. at 2, 24, 48 h post-surgery). On day 7, we assessed NLRP3/caspase-1 inflammasome activation, BDNF/TrkB/CREB/Erk signaling, PSD-95 expression, neuronal survival (Nissl staining), and working memory (Y-maze).
resultsLipo-Cur significantly suppressed NLRP3/caspase-1, restored p-CREB/CREB and p-TrkB/TrkB, normalized p-Erk/Erk, and upregulated PSD-95 (all p < 0.01). It also reduced neuronal loss, restored BDNF (p < 0.05), attenuated NLRP3 (p < 0.01), and improved Y-maze alternation (p < 0.001) without affecting locomotion.
conclusionThese findings suggest that liposomal curcumin exerts neuroprotective effects in the mPFC after ICH, likely through mechanisms involving suppression of NLRP3/caspase-1 and enhancement of BDNF/TrkB/CREB signaling. This supports its potential as a natural product-based therapeutic for stroke-induced cognitive impairment, though further mechanistic studies are warranted.
Indexed as
Identifiers
42753069What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.